Cartesian Therapeutics Inc (RNAC)
EBITDA Margin
-10671.90%
TTM · Period ending:
RNAC EBITDA Margin
Latest reported-10671.90%period ending
Latest reported-10671.90%period ending
RNAC TTM EBITDA Margin (-385.66% → -10671.90%)
TTM ebitda margin
High-resolution chart · PNG
RNAC ebitda margin history
Trailing twelve months (TTM). Each value covers four complete reported quarters.
| Period ending | EBITDA Margin |
|---|---|
| -10,671.9025% | |
| -8,932.338% | |
| -4,881.5159% | |
| -4,111.3657% | |
| -3,260.8187% | |
| -105.0508% | |
| -195.2715% | |
| -548.4% | |
| -455.6856% | |
| -1,046.1901% | |
| -903.8379% | |
| -92.6505% | |
| -64.7273% | |
| -13.7785% | |
| 35.2853% | |
| 37.0597% | |
| 40.7174% | |
| 44.3319% | |
| -6.6117% | |
| -50.0857% | |
| -88.3893% | |
| -257.348% | |
| -401.193% | |
| -576.5044% | |
| -1,011.7373% | |
| -890.4155% | |
| -774.9738% | |
| -5,698.3801% | |
| -6,131.5335% | |
| -6,463.8554% | |
| -6,964.2303% | |
| -398,935.2941% | |
| -151,386.3636% | |
| -91,524.2857% | |
| -30,607.2464% | |
| -1,854.4551% | |
| -1,228.8578% | |
| -682.0939% | |
| -422.5535% | |
| -373.5008% | |
| -320.5582% | |
| -351.1536% | |
| -385.6596% |